Study guide

8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

Key Takeaways Explain This Topic AI

Opioid receptors ( μ , κ , δ \mu, \kappa, \delta μ , κ , δ ) are G i / G o G_i/G_o G i ​ / G o ​ protein-coupled receptors whose activation inhibits adenylyl cyclase (decreasing intracellular cAMP), closes presynaptic voltage-gated C a 2 + Ca^{2+} C a 2 + channels (inhibiting neurotransmitter release), and opens postsynaptic inward-rectifying K + K^+ K + channels ( G I R K GIRK G I R K ), producing neuronal hyperpolarization.

Morphine is metabolized to active glucuronides: morphine-6-glucuronide (M6G), a μ \mu μ -agonist more potent than morphine (modestly so when given systemically, far more when given centrally), and morphine-3-glucuronide (M3G), which produces neurotoxicity and hyperalgesia; both accumulate in renal impairment, causing delayed, refractory respiratory depression.

Remifentanil contains an ester bond rapidly hydrolyzed by non-specific blood and tissue esterases, producing an invariant context-sensitive half-time of 3 to 4 minutes independent of infusion duration, hepatic function, or pseudocholinesterase; rapid cessation risks acute opioid tolerance and hyperalgesia.

Naloxone is a competitive opioid antagonist with a short duration of action (30-60 min); rapid reversal can precipitate a catastrophic sympathetic surge (pulmonary edema, arrhythmias, severe pain), while recurrence of respiratory depression (renarcotization) can occur once naloxone clears.

Paracetamol hepatotoxicity occurs when glucuronidation and sulfation pathways saturate, shunting metabolism through CYP2E1 to generate toxic N N N -acetyl- p p p -benzoquinone imine (NAPQI), which depletes hepatic glutathione; N N N -acetylcysteine restores glutathione and prevents centrilobular hepatic necrosis.

Last updated: October 2026

8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

Effective perioperative pain management hinges on multimodal analgesia: combining opioid agonists with non-opioid agents acting at distinct anatomical and molecular targets along the pain pathway. This approach maximizes analgesia while mitigating opioid-induced ventilatory depression, nausea, ileus, and physical dependence.

1. Opioid Receptor Classification and Intracellular Signaling

Opioid receptors belong to the rhodopsin-like superfamily of seven-transmembrane-spanning domain G G G -protein coupled receptors (GPCRs) . [ OPIOID RECEPTOR SUBTYPES ]

  • |
  • +-------------------------------------+-------------------------------------+
  • | | |
  • [ MU ($\mu$, MOR / MOP) ] [ KAPPA ($\kappa$, KOR / KOP) ] [ DELTA ($\delta$, DOR / DOP) ]
  • $\mu_1$: Supraspinal analgesia - Spinal analgesia - Spinal & supraspinal analgesia
  • $\mu_2$: Spinal analgesia, - Sedation, miosis - Modulation of mood & behavior
  • respiratory depression, - Dysphoria & hallucinations - Mild respiratory depression
  • bradycardia, constipation, miosis - Diuresis (inhibits ADH release) - Pro-convulsant at high doses
  • Agonists: Morphine, Fentanyl - Agonists: Dynorphins, Nalbuphine - Agonists: Enkephalins
  • Endogenous: $\beta$-Endorphin - Endogenous: Dynorphins - Endogenous: Enkephalins
  • Intracellular Signaling Cascade ( G i / G o G_i/G_o G i ​ / G o ​ Protein Coupling)

All three classical opioid receptors are coupled to pertussis toxin-sensitive inhibitory G G G -proteins ( G α i / G α o G_{\alpha i} / G_{\alpha o} G α i ​ / G α o ​ ) : Opioid Agonist Binds 7-TM Receptor

  • |
  • G-protein Heterotrimer Dissociates
  • |
  • +---------------------------+---------------------------+
  • | |
  • [ $G_{\alpha i}$ Subunit ] [ $G_{\beta\gamma}$ Dimer ]
  • | |
  • Inhibits Adenylyl Cyclase +-----------------------+
  • | | |
  • $\downarrow$ Intracellular cAMP [ Presynaptic ] [ Postsynaptic ]
  • | CLOSES $Ca^{2+}$ OPENS $K^+$ Channels
  • $\downarrow$ Protein Kinase A (PKA) Channels ($N, P/Q$) ($GIRK$ Channels)
  • | | |
  • Altered Gene Transcription Inhibits Exocytosis $K^+$ Efflux Produces
  • & Decreased Excitability of Glutamate, Neuronal Hyperpolarization
  • Substance P & CGRP

Adenylyl Cyclase Inhibition: The active G α i G_{\alpha i} G α i ​ subunit inhibits adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate ( ↓ cAMP \downarrow \text{cAMP} ↓ cAMP ) and downregulating Protein Kinase A (PKA) activity.

Presynaptic Calcium Channel Closure: The liberated G β γ G_{\beta\gamma} G β γ ​ subunit complex directly inhibits presynaptic voltage-gated N N N -type and P / Q P/Q P / Q -type calcium channels . Decreased intracellular C a 2 + Ca^{2+} C a 2 + influx blocks vesicular exocytosis of excitatory neurotransmitters (Substance P, glutamate, calcitonin gene-related peptide [CGRP]) from primary nociceptive afferent C and A δ A\delta A δ fibers in the substantia gelatinosa (Rexed lamina II) of the dorsal horn.

Postsynaptic Potassium Channel Opening: The G β γ G_{\beta\gamma} G β γ ​ dimer activates G G G -protein coupled inward-rectifying potassium ( G I R K GIRK G I R K ) channels , triggering rapid potassium efflux. This hyperpolarizes the postsynaptic spinothalamic projection neurons, making them refractory to excitatory depolarizing stimuli.

2. Pharmacokinetics and Pharmacodynamics of Clinical Opioids

Opioid Relative Potency (IV Morphine = 1) p K a pK_a p K a ​ % Unionized at pH 7.4 Octanol:Water Partition Coeff Active Metabolites Distinct Pharmacological Features

Morphine 1 8.0 ~20% 1.4 (Hydrophilic) M6G (potent analgesic), M3G (neurotoxic) Histamine release; active metabolites accumulate in renal failure

Fentanyl 100 8.4 ~8.5% 816 (Lipophilic) Norfentanyl (inactive) Rapid onset; termination by redistribution; context-sensitive t 1 / 2 t_{1/2} t 1/2 ​ increases with prolonged infusions

Alfentanil 10 - 20 6.5 ~90% 128 (Moderate) Inactive metabolites Ultra-rapid onset (<1 min) due to high unionized fraction; low V d V_d V d ​

Sufentanil 500 - 1000 8.0 ~20% 1757 (Highly lipophilic) Desmethylsufentanil (weak) Highest μ \mu μ -affinity; shorter context-sensitive t 1 / 2 t_{1/2} t 1/2 ​ than fentanyl

Remifentanil 100 - 200 7.1 ~65% 18 (Moderate) Remifentanil acid (inactive) Ester linkage ; hydrolyzed by blood/tissue esterases; context-sensitive t 1 / 2 ≈ 3 − 4 min t_{1/2} \approx 3-4\text{ min} t 1/2 ​ ≈ 3 − 4 min

Methadone 1 - 10 (variable) 8.3 ~10% Highly lipophilic EDDP (inactive) NMDA antagonist; SNRI activity; prolonged half-life (15-60+ h); QTc prolongation hazard

Tramadol 0.1 9.4 <5% Moderate O O O -desmethyltramadol (M1) Weak μ \mu μ -agonist + SNRI; requires CYP2D6; lowers seizure threshold

Morphine

Pharmacokinetics: Low lipid solubility slows blood-brain barrier penetration; clinical analgesic onset takes 15 to 30 minutes, peaking at 45 to 60 minutes.

Metabolism: Undergoes hepatic Phase II glucuronidation via UGT2B7 into two major metabolites:

Morphine-6-Glucuronide (M6G, ~10%): Crosses the blood-brain barrier; is a more potent μ \mu μ -agonist than morphine (estimates range from a few-fold systemically to much higher after central administration) and contributes analgesia and respiratory depression.

Morphine-3-Glucuronide (M3G, ~50-60%): Devoid of opioid analgesic activity; acts as a neurotoxin producing hyperalgesia, allodynia, myoclonus, and seizures.

Renal Failure Hazard: Both M6G and M3G depend exclusively on renal glomerular filtration for elimination. In renal failure, M6G accumulates, causing delayed, refractory, life-threatening respiratory depression, while M3G causes severe neurotoxicity.

Histamine Release: Stimulates mast cell degranulation, producing cutaneous flushing, pruritus, arterial hypotension, and bronchospasm.

Fentanyl and Alfentanil

Fentanyl: Highly lipophilic phenylpiperidine derivative (100 times more potent than morphine). Rapid onset within 2 to 3 minutes. Rapid termination after a single bolus is driven entirely by redistribution from brain to muscle and fat ( t 1 / 2 α ≈ 1 − 3 min t_{1/2\alpha} \approx 1-3\text{ min} t 1/2 α ​ ≈ 1 − 3 min ). However, after prolonged infusions, peripheral tissues saturate, causing fentanyl to leach back into the circulation and markedly prolonging its context-sensitive half-time (>250 min after a 4-hour infusion). High doses or rapid IV boluses trigger wooden chest syndrome (acute vocal cord closure and severe skeletal rigidity of the thoracic and abdominal musculature), treatable with neuromuscular blockers or naloxone.

Alfentanil: Rapid onset (<60 seconds). Although less lipophilic than fentanyl, its low p K a pK_a p K a ​ of 6.5 means that at physiological blood pH of 7.4, ~90% exists in the non-ionized (free base) state . Non-ionized molecules cross the lipophilic blood-brain barrier instantaneously. Small volume of distribution ( V d ≈ 0.4 − 1.0 L/kg V_d \approx 0.4-1.0\text{ L/kg} V d ​ ≈ 0.4 − 1.0 L/kg ) and high hepatic extraction via CYP3A4.

Remifentanil

Ester Linkage: Anilinopiperidine congener possessing a chemically vulnerable methyl ester moiety on the piperidine ring.

Metabolism: Rapidly hydrolyzed by non-specific blood and tissue esterases into remifentanil acid (GR90214), which has 1/4600th the potency of parent remifentanil. It is not metabolized by plasma pseudocholinesterase or red cell acetylcholinesterase.

Organ Independence: Metabolism is completely independent of hepatic and renal function, patient age, or pseudocholinesterase deficiencies.

Invariant Pharmacokinetics: Exhibits an ultra-short context-sensitive half-time of 3 to 4 minutes , which remains completely invariant regardless of whether the infusion runs for 20 minutes or 12 hours. Rapid blood-brain equilibration ( t 1 / 2 k e 0 ≈ 1 min t_{1/2}k_{e0} \approx 1\text{ min} t 1/2 ​ k e 0 ​ ≈ 1 min ).

Clinical Considerations: Stopping an infusion leads to complete loss of analgesia within 5 to 10 minutes; proactive transition to longer-acting analgesics is mandatory. High-dose infusions are prone to inducing acute receptor desensitization, tolerance, and Opioid-Induced Hyperalgesia (OIH) via NMDA receptor activation.

Methadone and Tramadol

Methadone: Racemic mixture: R R R -methadone is a potent μ \mu μ -agonist; S S S -methadone is a non-competitive NMDA receptor antagonist and serotonin/norepinephrine reuptake inhibitor (SNRI) . Highly effective for complex neuropathic pain. High bioavailability (>80%), large volume of distribution, and a prolonged, variable elimination half-life ( 15 to 60+ hours ). Hazard: dose-dependent blockade of cardiac delayed rectifier potassium channels ( I K r I_{Kr} I Kr ​ / hERG), causing QTc prolongation and Torsades de Pointes .

Tramadol: Dual mechanism: weak μ \mu μ -agonist combined with central inhibition of noradrenaline and serotonin reuptake. Prodrug: bioactivated by hepatic CYP2D6 into O O O -desmethyltramadol (M1 metabolite) , which has 200- to 300-fold higher affinity for μ \mu μ -receptors than parent tramadol. Poor CYP2D6 metabolizers gain inadequate analgesia, whereas ultra-rapid metabolizers risk severe respiratory depression. Lowers seizure threshold and carries high risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs.

3. Opioid Reversal: Naloxone

Naloxone is a pure, non-selective competitive antagonist at μ \mu μ , κ \kappa κ , and δ \delta δ opioid receptors.

Pharmacokinetics: Onset within 1 to 2 minutes IV. Duration of action is only 30 to 60 minutes (elimination half-life ~60-90 min), which is significantly shorter than the elimination half-life of morphine, hydromorphone, methadone, or transdermal fentanyl.

Renarcotization Hazard: Once naloxone clears, persistent agonist molecules rebind to unoccupied receptors, causing recurrence of hypoventilation, coma, and apnea. Patients must be monitored continuously for at least 2 to 4 hours post-reversal, and a continuous naloxone infusion (dosed at two-thirds of the initial successful bolus per hour) may be required.

Acute Sympathetic Surge: Over-rapid or excessive naloxone administration abruptly strips both exogenous and endogenous opioids from receptors. This produces an intense surge of endogenous catecholamines, precipitating excruciating pain, severe hypertension, tachycardia, ventricular arrhythmias, myocardial infarction, and acute non-cardiogenic pulmonary edema . Naloxone must be titrated in small aliquots (20 to 40 μ g \mu\text{g} μ g every 2 to 3 minutes) until spontaneous ventilation returns without completely reversing analgesia.

  • 4. Non-Opioid Analgesic Agents
  • Paracetamol (Acetaminophen)

Mechanism of Action: Central inhibition of prostaglandin synthesis through selective inhibition of the peroxidase catalytic activity of cyclooxygenase enzymes (COX-1 and COX-2) in cellular environments with low peroxide concentrations (such as the brain). Devoid of peripheral anti-inflammatory activity because high lipid peroxide concentrations in inflamed peripheral tissues inactivate paracetamol. Modulates descending serotonergic inhibitory pathways and the endocannabinoid system (metabolized to AM404, which inhibits cellular reuptake of anandamide).

Dosing and Limits: Maximum dose is 4 g/day 4\text{ g/day} 4 g/day ( 1 g 1\text{ g} 1 g every 6 hours) in healthy adults; reduced to ≤ 2 − 3 g/day \le 2-3\text{ g/day} ≤ 2 − 3 g/day in chronic alcoholism, malnutrition, low body weight (<50 kg), or preexisting liver disease.

  • Overdose and Hepatotoxicity Pathophysiology: Paracetamol Ingestion
  • |
  • +-----------------------------------+-----------------------------------+
  • | (90% - Normal Therapeutic Pathways) | (5-10% - Toxic Pathway)
  • v v
  • Hepatic Glucuronidation & Sulfation CYP2E1 Oxidation
  • (Saturated in Overdose) |
  • | v
  • Non-toxic Urinary Conjugates [ NAPQI ]
  • (Highly Toxic Electrophile)
  • |
  • +-----------------------------------+-----------------------------------+
  • | (Glutathione Stores Normal) | (Glutathione Depleted by >70%)
  • v v
  • Glutathione Conjugate NAPQI Binds Hepatocyte Proteins
  • (Mercapturic Acid - Non-toxic) Mitochondrial Permeability Transition
  • Centrilobular Hepatic Necrosis

Antidote: N N N -Acetylcysteine (NAC) . Acts as a cysteine precursor to replenish depleted intracellular hepatic glutathione stores and directly conjugates free NAPQI as a glutathione substitute. Most effective when administered within 8 hours of acute ingestion.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism: Inhibit cyclooxygenase (prostaglandin H 2 H_2 H 2 ​ synthase), halting the conversion of arachidonic acid into pro-inflammatory prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 ​ , PG I 2 ​ ) and thromboxane A 2 A_2 A 2 ​ ( T X A 2 TXA_2 TX A 2 ​ ):

Non-selective COX Inhibitors: Ibuprofen, ketorolac, diclofenac, naproxen (inhibit both COX-1 and COX-2).

Selective COX-2 Inhibitors: Celecoxib, parecoxib, etoricoxib (sparing COX-1).

Organ System Toxicities:

Gastrointestinal Ulceration: COX-1 inhibition suppresses mucosal synthesis of cytoprotective P G E 2 PGE_2 PG E 2 ​ and P G I 2 PGI_2 PG I 2 ​ (which normally stimulate gastric mucus and bicarbonate secretion while maintaining mucosal blood flow), leading to peptic ulceration and life-threatening gastrointestinal hemorrhage.

Renal Dysfunction and Acute Kidney Injury (AKI): In states of decreased effective circulating volume (hypovolemia, congestive heart failure, sepsis, cirrhosis), renal perfusion is critically maintained by vasodilatory prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 ​ , PG I 2 ​ ) that dilate the afferent glomerular arteriole . NSAID administration uncouples this compensatory mechanism, triggering severe afferent arteriolar vasoconstriction, sharp drops in glomerular filtration rate (GFR), and acute tubular necrosis.

Platelet Dysfunction: Non-selective NSAIDs block platelet COX-1, halting synthesis of thromboxane A 2 A_2 A 2 ​ ( T X A 2 TXA_2 TX A 2 ​ ) and impairing platelet aggregation. Aspirin binds irreversibly via acetylation (persisting for the 7- to 10-day lifespan of the platelet); traditional NSAIDs bind reversibly. Selective COX-2 inhibitors spare platelet COX-1 and do not impair primary hemostasis; however, by suppressing endothelial prostacyclin ( P G I 2 PGI_2 PG I 2 ​ , a vasodilator and platelet inhibitor) while leaving platelet T X A 2 TXA_2 TX A 2 ​ unchecked, selective COX-2 inhibitors create a pro-thrombotic state that increases myocardial infarction and stroke risks.

Bronchospasm in AERD: In Aspirin-Exacerbated Respiratory Disease (Samter's triad: asthma, chronic rhinosinusitis with nasal polyps, and aspirin sensitivity), COX inhibition shunts arachidonic acid into the 5-lipoxygenase (5-LOX) pathway. This drives massive overproduction of cysteinyl leukotrienes ( L T C 4 , L T D 4 , L T E 4 LTC_4, LTD_4, LTE_4 L T C 4 ​ , L T D 4 ​ , L T E 4 ​ ), triggering severe, life-threatening bronchospasm.

Gabapentinoids: Gabapentin and Pregabalin

Structure and Target: Structural analogs of γ \gamma γ -aminobutyric acid that do not bind to G A B A A GABA_A G A B A A ​ or G A B A B GABA_B G A B A B ​ receptors, nor do they alter GABA synthesis or reuptake.

Mechanism: Bind selectively to the auxiliary α 2 δ − 1 \alpha_2\delta-1 α 2 ​ δ − 1 and α 2 δ − 2 \alpha_2\delta-2 α 2 ​ δ − 2 subunits of presynaptic voltage-gated calcium channels in the dorsal horn of the spinal cord. Binding inhibits forward trafficking of calcium channels to the presynaptic terminal membrane, reducing calcium influx upon nerve depolarization. This downregulates the exocytotic release of excitatory neurotransmitters (glutamate, Substance P, CGRP), dampening central sensitization and hyperalgesia.

Clinical Indications: First-line treatment for chronic neuropathic pain (post-herpetic neuralgia, diabetic neuropathy) and key components of opioid-sparing perioperative multimodal analgesia protocols.

Pharmacokinetics and Toxicity: Excreted 100% unchanged in urine by glomerular filtration; doses must be reduced in renal impairment. Primary adverse effects include dose-dependent sedation, dizziness, ataxia, peripheral edema, and synergistic respiratory depression when co-administered with opioids.